Why Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading Today

NEW YORK (TheStreet) -- Endocyte  (ECYT) plummeted approximately 25% in after-hours trading on Tuesday after the biopharmaceutical company announced Merck  (MRK), through a subsidiary, would no longer pursue development of vintafolide, aka Vynfinit.

Endocyte said it has regained worldwide rights to the ovarian cancer drug and will evaluate Vynfinit "for future development opportunities."

Endocyte's stock plummeted on May 2 when the drug failed in a Phase III study. For more on that, read TheStreet's Adam Feuerstein's story here.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 23.7% to $5.89 at 4:34 p.m.

ECYT Price Chart

ECYT Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Focused on Stock Picking Through This Volatility

Focused on Stock Picking Through This Volatility

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock